Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
29.74 (1y: -5%)
Market Cap 22.5 B P/E(ttm) 31.60
Enterprise Value 27.41 B P/B 2.40
CVE- NYSE (USA)
Cenovus Energy, Inc.
Not Rated
Top Ranked Predictable Companies
$29.74
Switch to:
Jump to: Guru Trade | Guru Ownership | Insider Trade

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M22,500Revenue $M16,891Net Margin (%)5.8Z-Score1.9
Enterprise Value $M27,316EPS $1.0Operating Margin %12.2F-Score7
P/E(ttm))31.6Cash Flow Per Share $3.4Pre-tax Margin (%)10.3Higher ROA y-yY
Price/Book2.410-y EBITDA Growth Rate %0Quick Ratio0.8Cash flow > EarningsY
Price/Sales1.45-y EBITDA Growth Rate %0Current Ratio1.5Lower Leverage y-yY
Price/Cash Flow9.9y-y EBITDA Growth Rate %-18.8ROA % (ttm)4.1Higher Current Ratio y-yY
Dividend Yield %3.0Insider Buy (3m)74ROE % (ttm)10.1Less Shares Outstanding y-yN
Payout Ratio %67.2Shares Outstanding M755ROI % (ttm)11.0Gross Margin Increase y-yY

Gurus Latest Trades with CVE

Please Subscribe to see portfolio changes after the end of the last quarter. Real Time Picks are included for Premium Members only! Plans start from as little as $299/year.

7-Day FREE TRIAL
Select Gurus | Default List of Gurus | All Investors | Mutual Fund Gurus | Hedge Fund Gurus
Number of guru portfolios checked: 51.
Total Records: 29   Page:1 2 Next Page
TickerGuruDate Action
 Impactdown Price Range
(Average)* 		Current Price Change from Average Comment Current Shares
CVELou Simpson 2013-03-31 Add0.85%$30.77 - $34.25
($32.62)		 $ 29.87-8%Add 18.67%2,765,467
CVERay Dalio 2013-03-31 Reduce-0.02%$30.77 - $34.25
($32.62)		 $ 29.87-8%Reduce -29.34%126,900
CVERay Dalio 2012-12-31 Add0.01%$32.29 - $35.79
($33.9)		 $ 29.87-12%Add 22.43%179,600
CVEMario Gabelli 2012-12-31 Sold Out -0.0032%$32.29 - $35.79
($33.9)		 $ 29.87-12%Sold Out0
CVELou Simpson 2012-09-30 Add0.82%$30.31 - $36.78
($33.03)		 $ 29.87-10%Add 13.54%2,322,866
CVEMartin Whitman 2012-07-31 Sold Out -1.1%$29.42 - $35.95
($31.82)		 $ 29.87-6%Sold Out0
CVEJean-Marie Eveillard 2012-06-30 Add0.27%$29.42 - $36.55
($32.63)		 $ 29.87-8%Add 28.64%9,386,052
CVEPRIMECAP Management 2012-06-30 Reduce-0.05%$29.42 - $36.55
($32.63)		 $ 29.87-8%Reduce -22.47%3,176,714
CVERay Dalio 2012-06-30 Reduce-0.04%$29.42 - $36.55
($32.63)		 $ 29.87-8%Reduce -36.96%124,700
CVERay Dalio 2012-03-31 Add0.05%$33.15 - $39.44
($24.23)		 $ 29.8723%Add 80.47%197,800
CVEJean-Marie Eveillard 2011-12-31 Add0.15%$28.78 - $36.59
($16.81)		 $ 29.8778%Add 15.73%7,219,912
CVERay Dalio 2011-12-31 Add0.05%$28.78 - $36.59
($16.81)		 $ 29.8778%Add 705.88%109,600
CVEJean-Marie Eveillard 2011-09-30 Add0.12%$29.76 - $40.21
($35.44)		 $ 29.87-16%Add 14.44%6,238,381
CVEMario Gabelli 2011-09-30 Reduce$29.76 - $40.21
($35.44)		 $ 29.87-16%Reduce -24.7%22,258
CVERay Dalio 2011-09-30 Reduce-0.01%$29.76 - $40.21
($35.36)		 $ 29.87-16%Reduce -50%13,600
CVEDodge & Cox 2011-06-30 Sold Out $33.4 - $40.24
($35.95)		 $ 29.87-17%Sold Out0
CVEMario Gabelli 2011-06-30 Reduce$33.4 - $40.24
($35.95)		 $ 29.87-17%Reduce -23.54%29,558
CVEMario Gabelli 2011-03-31 Buy 0.01%$31.59 - $39.7
($35.51)		 $ 29.87-16%New holding, 38658 sh.38,658
CVEDodge & Cox 2011-03-31 Reduce$31.59 - $39.7
($35.51)		 $ 29.87-16%Reduce -65.95%5,839
CVEJean-Marie Eveillard 2010-09-30 Add0.33%$25 - $29.83
($27.56)		 $ 29.878%Add 53.8%5,193,339
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.
Total Records: 29   Page:1 2 Next Page

CVE is held by these Gurus:

Select Gurus | Default List of Gurus | All Investors | Mutual Fund Gurus | Hedge Fund Gurus
Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CVE Lou Simpson 2013-03-312,765,4670.375.4+18.67%
CVE Jean-Marie Eveillard 2013-03-319,881,6961.311+2.14%
CVE PRIMECAP Management 2013-03-312,502,5000.330.11-12.05%
CVE Ray Dalio 2013-03-31126,9000.020.04-29.34%
Premium Most recent portfolio changes are included for Premium Members only!


CVE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Thomas, Wayne RichardSenior Officer 2013-02-28Sell1,100$33.21-10.42view
Thomas, Wayne RichardSenior Officer 2013-02-28Sell75$33.2-10.39view
McIntosh, SheilaSenior Officer 2013-02-28Sell5,000$33.33-10.74view
McIntosh, SheilaSenior Officer 2013-02-28Sell7,500$33.22-10.45view
Swystun, DonaldSenior Officer 2013-02-28Sell23,000$33.21-10.42view
Swystun, DonaldSenior Officer 2013-02-28Sell20,000$33.31-10.69view
Thomas, Wayne RichardSenior Officer 2013-02-28Sell1,700$33.22-10.45view
Thomas, Wayne RichardSenior Officer 2012-02-22Sell500$39.01-23.74view

Press Releases about CVE:

Quarterly/Annual Reports about CVE:

    News about CVE:

    Articles On GuruFocus.com
    Bill Nygren's Oakmark Select Fund - First Quarter 2013 Commentary Apr 23 2013 
    Global Malaise Not Affecting These Countries (Or Companies) Mar 10 2013 
    New Guru Lou Simpson’s Top-Yielding Stocks Jan 04 2013 
    Third Avenue Value Fund Buys Devon Energy, Symantec, Stanley Furniture, Sells Forest City, Cenovus E Sep 28 2012 
    Cheapest Large Caps with Highest Expected Growth as of April 2012 Apr 23 2012 
    Stocks With Dividend Growth From Last Week (February 13-19, 2012) Feb 19 2012 
    Bill Nygren's Quarterly Shareholder Letter and Commentary Apr 12 2011 
    Weekly Top Insider Buys: CVC, WU, CLR, TJX, CVE Jan 30 2011 
    Why the Peak in Peak Oil is a Myth Oct 29 2010 
    Preparing Your Portfolio For the Most Important Macro Issue of the Upcoming Decade – Several Actio Sep 23 2010 

    Add Notes, Comments or Ask Questions

    Comments

    No comment yet
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
    Free 7-day Trial
    FEEDBACK